Abstract
Baricitinib, a JAK1/2 inhibitor, has been expanding its role as a therapeutic agent with recent FDA approval for dermatologic use with alopecia areata. Clinical trials are underway for further use of baricitinib for severe atopic dermatitis and multiple off-label uses in inflammatory dermatologic conditions such as lichen planus have been suggested. Few reports exist of patients with concomitant alopecia areata and lichen planus treated with baricitinib. We present a case of refractory oral lichen planus with marked improvement within one month following treatment with once daily baricitinib. Our case adds to the growing body of literature regarding the therapeutic benefits of JAK inhibitors in the treatment of lichen planus.
Publisher
Athenaeum Scientific Publishers
Reference7 articles.
1. Arnold DL, Krishnamurthy K. Lichen Planus. In: StatPearls. StatPearls Publishing. 2022.
2. Lavanya N, Rao U, Jayanthi P, Ranganathan K. Oral lichen planus: An update on pathogenesis and treatment. J Oral Maxillofac Pathol. 2011;15(2):127.
3. Ahmad A, Zaheer M, Balis FJ. Baricitinib. In: StatPearls. StatPearls Publishin. 2022.
4. Shao S, Tsoi LC, Sarkar MK, et al. IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med. 2019;11(511):eaav7561
5. Abduelmula A, Bagit A, Mufti A, Yeung KCY, Yeung J. The use of janus kinase inhibitors for lichen planus: an evidence-based review. J Cutan Med Surg. 2023;27(3):271-6.